Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.…
How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Tyra Biosciences (NASDAQ: TYRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 20.12 USD on 20 November 2026, up 40.5% over 52 weeks. Its 52-week range is 13.83 USD to 40.65 USD: the price is 50.5% below the high and 45.5% above the low.
Its market capitalisation is 1.39B USD.
Tyra Biosciences reports return on equity of -46.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 695.08M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 47.55 USD is 136.3% above the current price. The next earnings report is expected on 2 March 2027.